Testosterone cypionateCAS# 58-20-8 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 58-20-8 | SDF | Download SDF |
| PubChem ID | 441404 | Appearance | Powder |
| Formula | C27H40O3 | M.Wt | 412.6 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate | ||
| SMILES | CC12CCC3C(C1CCC2OC(=O)CCC4CCCC4)CCC5=CC(=O)CCC35C | ||
| Standard InChIKey | HPFVBGJFAYZEBE-ZLQWOROUSA-N | ||
| Standard InChI | InChI=1S/C27H40O3/c1-26-15-13-20(28)17-19(26)8-9-21-22-10-11-24(27(22,2)16-14-23(21)26)30-25(29)12-7-18-5-3-4-6-18/h17-18,21-24H,3-16H2,1-2H3/t21-,22-,23-,24-,26-,27-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Testosterone cypionate Dilution Calculator
Testosterone cypionate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.4237 mL | 12.1183 mL | 24.2365 mL | 48.4731 mL | 60.5914 mL |
| 5 mM | 0.4847 mL | 2.4237 mL | 4.8473 mL | 9.6946 mL | 12.1183 mL |
| 10 mM | 0.2424 mL | 1.2118 mL | 2.4237 mL | 4.8473 mL | 6.0591 mL |
| 50 mM | 0.0485 mL | 0.2424 mL | 0.4847 mL | 0.9695 mL | 1.2118 mL |
| 100 mM | 0.0242 mL | 0.1212 mL | 0.2424 mL | 0.4847 mL | 0.6059 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Methyltestosterone
Catalog No.:BCC9045
CAS No.:58-18-4
- Aminophenazone
Catalog No.:BCC8815
CAS No.:58-15-1
- Pyrimethamine
Catalog No.:BCC2307
CAS No.:58-14-0
- Caffeine
Catalog No.:BCN5807
CAS No.:58-08-2
- Bax inhibitor peptide P5
Catalog No.:BCC2393
CAS No.:579492-83-4
- Bax inhibitor peptide V5
Catalog No.:BCC2394
CAS No.:579492-81-2
- Officinalisinin I
Catalog No.:BCN2825
CAS No.:57944-18-0
- L(+)-Asparagine Monohydrate
Catalog No.:BCC8332
CAS No.:5794-13-8
- Z-Cys(Z)-OH
Catalog No.:BCC2784
CAS No.:57912-35-3
- Corynoxidine
Catalog No.:BCN6798
CAS No.:57906-85-1
- 19-Nor-4-hydroxyabieta-8,11,13-trien-7-one
Catalog No.:BCN1411
CAS No.:57906-31-7
- o-Anisic acid
Catalog No.:BCC9108
CAS No.:579-75-9
- Testosterone
Catalog No.:BCN2193
CAS No.:58-22-0
- Menadione
Catalog No.:BCN8351
CAS No.:58-27-5
- Desipramine hydrochloride
Catalog No.:BCC7553
CAS No.:58-28-6
- Promethazine HCl
Catalog No.:BCC5480
CAS No.:58-33-3
- Prochlorperazine
Catalog No.:BCC3846
CAS No.:58-38-8
- Tetrabenazine
Catalog No.:BCC5277
CAS No.:58-46-8
- Theophylline
Catalog No.:BCN1258
CAS No.:58-55-9
- Pyridoxine HCl
Catalog No.:BCC4835
CAS No.:58-56-0
- Puromycin dihydrochloride
Catalog No.:BCC7860
CAS No.:58-58-2
- Puromycin aminonucleoside
Catalog No.:BCC1873
CAS No.:58-60-6
- Adenosine
Catalog No.:BCN5796
CAS No.:58-61-7
- Inosine
Catalog No.:BCN3841
CAS No.:58-63-9
Effect of testosterone cypionate and stanozolol on the heart of young trained mice: A morphometric study.[Pubmed:30772437]
Steroids. 2019 May;145:19-22.
Testosterone cypionate and Stanozolol are Anabolic-Androgenic Steroids (AAS) which are synthetic substances that possess functions similar to testosterone. The use of these substances has increased considerably among youngsters and sports practitioners aiming better performance of with aesthetic purposes. The major concern is the effects caused by the inappropriate use of the substances, such as hypertension, myocardial ischemia, and left ventricle hypertrophy. The objective of the present research was to measure the diameter of the left ventricle lumen and the thickness of the left ventricle myocardium in mice submitted to supraphysiological doses of AAS. A total of 30 female Swiss mice were used in the experiments. The animals received supraphysiological doses of the AAS for 30days, and during the treatment period, they were put to swim in intercalated days. After treatment animals were euthanized and slides were made from the hearts for measurements. Results demonstrated that both AAS changed significantly the heart morphology: Testosterone cypionate led to an increase in the ventricular lumen and stanozolol increased left ventricle myocardium thickness. In conclusion, the use of AAS in supraphysiological doses can change the heart morphology and can lead to serious health consequences.
